|
Gene: TRMT112 |
Gene summary for TRMT112 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TRMT112 | Gene ID | 51504 |
Gene name | tRNA methyltransferase activator subunit 11-2 | |
Gene Alias | HSPC152 | |
Cytomap | 11q13.1 | |
Gene Type | protein-coding | GO ID | GO:0000154 | UniProtAcc | Q9UI30 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51504 | TRMT112 | P11T-E | Human | Esophagus | ESCC | 5.60e-37 | 2.32e+00 | 0.1426 |
51504 | TRMT112 | P12T-E | Human | Esophagus | ESCC | 2.63e-86 | 2.03e+00 | 0.1122 |
51504 | TRMT112 | P15T-E | Human | Esophagus | ESCC | 1.79e-31 | 1.12e+00 | 0.1149 |
51504 | TRMT112 | P16T-E | Human | Esophagus | ESCC | 8.24e-70 | 1.62e+00 | 0.1153 |
51504 | TRMT112 | P17T-E | Human | Esophagus | ESCC | 6.75e-29 | 1.84e+00 | 0.1278 |
51504 | TRMT112 | P19T-E | Human | Esophagus | ESCC | 2.79e-18 | 2.49e+00 | 0.1662 |
51504 | TRMT112 | P20T-E | Human | Esophagus | ESCC | 1.15e-58 | 1.77e+00 | 0.1124 |
51504 | TRMT112 | P21T-E | Human | Esophagus | ESCC | 1.41e-95 | 2.97e+00 | 0.1617 |
51504 | TRMT112 | P22T-E | Human | Esophagus | ESCC | 2.63e-72 | 1.54e+00 | 0.1236 |
51504 | TRMT112 | P23T-E | Human | Esophagus | ESCC | 3.36e-65 | 2.16e+00 | 0.108 |
51504 | TRMT112 | P24T-E | Human | Esophagus | ESCC | 6.54e-47 | 1.24e+00 | 0.1287 |
51504 | TRMT112 | P26T-E | Human | Esophagus | ESCC | 1.61e-82 | 1.92e+00 | 0.1276 |
51504 | TRMT112 | P27T-E | Human | Esophagus | ESCC | 1.72e-35 | 1.18e+00 | 0.1055 |
51504 | TRMT112 | P28T-E | Human | Esophagus | ESCC | 2.30e-81 | 2.26e+00 | 0.1149 |
51504 | TRMT112 | P30T-E | Human | Esophagus | ESCC | 1.85e-45 | 2.40e+00 | 0.137 |
51504 | TRMT112 | P31T-E | Human | Esophagus | ESCC | 2.58e-84 | 2.00e+00 | 0.1251 |
51504 | TRMT112 | P32T-E | Human | Esophagus | ESCC | 8.69e-103 | 2.85e+00 | 0.1666 |
51504 | TRMT112 | P36T-E | Human | Esophagus | ESCC | 1.60e-41 | 2.17e+00 | 0.1187 |
51504 | TRMT112 | P37T-E | Human | Esophagus | ESCC | 3.17e-74 | 2.80e+00 | 0.1371 |
51504 | TRMT112 | P38T-E | Human | Esophagus | ESCC | 5.36e-29 | 1.91e+00 | 0.127 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
GO:00063646 | Breast | Precancer | rRNA processing | 35/1080 | 225/18723 | 7.90e-08 | 4.60e-06 | 35 |
GO:00160726 | Breast | Precancer | rRNA metabolic process | 36/1080 | 236/18723 | 8.59e-08 | 4.84e-06 | 36 |
GO:00344705 | Breast | Precancer | ncRNA processing | 42/1080 | 395/18723 | 9.91e-05 | 1.83e-03 | 42 |
GO:00346604 | Breast | Precancer | ncRNA metabolic process | 45/1080 | 485/18723 | 1.15e-03 | 1.26e-02 | 45 |
GO:002261314 | Breast | IDC | ribonucleoprotein complex biogenesis | 83/1434 | 463/18723 | 2.01e-13 | 5.20e-11 | 83 |
GO:004225414 | Breast | IDC | ribosome biogenesis | 52/1434 | 299/18723 | 1.90e-08 | 1.32e-06 | 52 |
GO:000636414 | Breast | IDC | rRNA processing | 35/1434 | 225/18723 | 4.59e-05 | 1.03e-03 | 35 |
GO:001607214 | Breast | IDC | rRNA metabolic process | 36/1434 | 236/18723 | 5.48e-05 | 1.17e-03 | 36 |
GO:002261324 | Breast | DCIS | ribonucleoprotein complex biogenesis | 83/1390 | 463/18723 | 3.65e-14 | 1.09e-11 | 83 |
GO:004225423 | Breast | DCIS | ribosome biogenesis | 52/1390 | 299/18723 | 6.73e-09 | 5.44e-07 | 52 |
GO:000636422 | Breast | DCIS | rRNA processing | 35/1390 | 225/18723 | 2.41e-05 | 5.62e-04 | 35 |
GO:001607222 | Breast | DCIS | rRNA metabolic process | 36/1390 | 236/18723 | 2.86e-05 | 6.42e-04 | 36 |
GO:003447011 | Breast | DCIS | ncRNA processing | 44/1390 | 395/18723 | 4.56e-03 | 3.49e-02 | 44 |
GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
GO:004225410 | Cervix | CC | ribosome biogenesis | 62/2311 | 299/18723 | 2.48e-05 | 4.27e-04 | 62 |
GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
GO:00349685 | Cervix | CC | histone lysine methylation | 27/2311 | 115/18723 | 6.61e-04 | 6.09e-03 | 27 |
GO:00165715 | Cervix | CC | histone methylation | 30/2311 | 141/18723 | 1.88e-03 | 1.39e-02 | 30 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TRMT112 | SNV | Missense_Mutation | c.214N>A | p.Glu72Lys | p.E72K | Q9UI30 | protein_coding | tolerated(0.51) | benign(0.038) | TCGA-A8-A091-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD | |
TRMT112 | SNV | Missense_Mutation | c.236N>G | p.Glu79Gly | p.E79G | Q9UI30 | protein_coding | tolerated(0.06) | benign(0.078) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TRMT112 | SNV | Missense_Mutation | c.317N>G | p.Met106Arg | p.M106R | Q9UI30 | protein_coding | tolerated(0.41) | benign(0) | TCGA-E2-A1L7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
TRMT112 | SNV | Missense_Mutation | novel | c.127N>A | p.Ala43Thr | p.A43T | Q9UI30 | protein_coding | tolerated(0.46) | benign(0.026) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TRMT112 | SNV | Missense_Mutation | novel | c.59N>A | p.Gly20Asp | p.G20D | Q9UI30 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
TRMT112 | SNV | Missense_Mutation | novel | c.287N>T | p.Gly96Val | p.G96V | Q9UI30 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-52-7812-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | paclitaxel | PD |
TRMT112 | SNV | Missense_Mutation | novel | c.218N>C | p.Gly73Ala | p.G73A | Q9UI30 | protein_coding | tolerated(0.55) | benign(0.101) | TCGA-77-7463-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TRMT112 | insertion | Frame_Shift_Ins | rs762738556 | c.46_47insG | p.Val16GlyfsTer33 | p.V16Gfs*33 | Q9UI30 | protein_coding | TCGA-CV-A45W-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |